% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • blehair Jun 26, 2013 7:41 PM Flag

    250k shares sold out of a portfolio of millions of shares from 1 group

    That's all it is. Stock is up +300%. Who gives a dam what those form 4s mean. Those institutions are there to make money, they are up 300% before data has even been released, what a steal for them. They can de-risk their portfolio and in the event data is as superb as I expect it, they could buy back in on a single order during that super high volume day.

    Anyone who is letting Beacon's trading dictate their investment in this company deserves to lose their money. Anyone who has done any DD into this company knows to fully expect superb efficacy and durability results vs TOBI (and Cayston by proxy), given both the likely high patient population with historical TOBI use and P2 data thus far.

    The only thing in doubt is the safety profile, but trial catalysts rarely ever trade down on bad safety data unless it involves deaths, auto-immune events, or other SAEs, none of which are expected from Arikace. Safety is more heavily judged during the NDA process. Anyone can understand efficacy data which is why trial catalysts generally trade on those.

    Veteran bio catalyst traders look at INSM chart and know that it's a good one for a catalyst. Sell-offs before catalysts have shaken out the weak holders who drop big sell orders post-catalyst into the hands of shorts covering which allows shorts to cover w/o causing major squeeze.

    We are going to pop big w/ upcoming data, no doubt about it, this is a very efficacious product that CF and NTM population are in need of.

11.83-0.05(-0.42%)May 27 4:00 PMEDT